Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Capital Expenditures (2022)

BioXcel Therapeutics (BTAI) has 1 years of Capital Expenditures data on record, last reported at $19000.0 in Q2 2022.

  • For Q2 2022, Capital Expenditures changed N/A year-over-year to $19000.0; the TTM value through Sep 2023 reached $19000.0, changed N/A, while the annual FY2023 figure was $20000.0, 85.61% down from the prior year.
  • Capital Expenditures reached $19000.0 in Q2 2022 per BTAI's latest filing, down from $120000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $120000.0 in Q1 2022 and bottomed at $19000.0 in Q2 2022.